Ruiguang Kangtai Completes RMB 55 Million Financing to Accelerate Automated Production Base Development

Shenzhen Raycome Health Technology Co., Ltd. announced the completion of a funding round led byOriental Fortune CapitalLead Investor, Under Gree GroupGree Financial InvestmentCo-investment totaling RMB 55 million in financing and completion of industrial and commercial change registration procedures. Actively engaging through “investment-driven attraction,” Raycome Health willComprehensively build an automated production base in Zhuhai, providing "chip power" for the high-quality economic development of Zhuhai.

Shenzhen Raycome Health Technology Co., Ltd. was included in the “List of Enterprises Proposed for Inclusion and Promotion in the Zhuhai High-Growth Innovative Enterprise (Unicorn Enterprise) Incubation Pool,” released by the Zhuhai Municipal Science and Technology Innovation Bureau, and will fully build its Zhuhai automated production base in 2021.The overall planned area exceeds 30,000 square meters, primarily divided into production, laboratory, testing, quality control, and warehousing and logistics sections.。The new base will leverage automated production technologies to boost capacity and comprehensively upgrade the manufacturing supply chain, ensuring improvements in product quality, cost control, and production efficiency. This will provide strong support for launching a new business model for pulse wave blood pressure monitors, significantly accelerating market expansion and reinforcing its absolute dominance in market share.

After more than a decade of cultivation in the hypertension market, Raycome Health has accumulated substantial talent and technical reserves. The company has established blood pressure products as its core, optimized its product portfolio under the Medical Device Registrant System, and achieved synergistic development across diversified business lines. Centered on the broader health ecosystem, Raycome Health is strategically mapping out the entire health industry chain, exploring new application fields, and expanding its product range. New categories now span multiple areas, including laser medical devices, respiratory oxygen supply, blood oxygen and glucose monitoring, and home care.

Raycome Health is a national high-tech enterprise dedicated to providing integrated hardware and software solutions for blood pressure monitoring, featuring its independently developed fourth-generation internationally patented dual-tube, dual-sensor technology for precise blood pressure measurement—The pulse wave blood pressure measurement method has been filed for invention patents in over 40 countries worldwide and has obtained patent grants in nine countries and regions.The pulse wave blood pressure monitor has undergone clinical validation at more than 20 large Grade A tertiary hospitals in China, with over 10 academic papers published. It has been successively designated as the specified blood pressure measurement device by the Chinese Hypertension League, the National Center for Cardiovascular Diseases, the National Big Data Joint Laboratory for Hypertension, and the National Medical Consortium for Hypertension. The product is available in more than 20 countries and regions worldwide, including the United States, Russia, Thailand, and Spain.

Invention Patent for Pulse Wave Blood Pressure Measurement Method

In terms of market strategic layout, Raycome Health has established a dual-drive model combining “soft” and “hard” solutions, as well as online and offline channels. Through traditional offline channels, PulseWave blood pressure monitors have entered over 10,000 medical institutions in China, ranking first among domestic brands in market share within the medical institution channel. In niche segments such as all-in-one health kiosks, smart healthcare, and hemodialysis, PulseWave blood pressure monitors maintain a significant lead in market share. By leveraging its high-end medical reputation and radiating influence to drive traffic to the consumer (C-end) market, the company has created blockbuster product combinations, expanded its product lines, and diversified its categories, achieving explosive growth across all consumer platforms. With its international business expansion and products certified by CE, AAMI, and ESH, the company has begun establishing a country-level agency system centered on distribution channels, having already signed agreements with agents in more than twenty countries.

Leveraging precise big data, mobile healthcare, and artificial intelligence technologies, the Pulse Wave Blood Pressure Monitor is dedicated to developing an "Internet + Blood Pressure Management" system. It provides customers with comprehensive services, including self-service blood pressure screening, ambulatory blood pressure monitoring, statistical analysis of home blood pressure monitoring data, health alerts, and healthy lifestyle guidance, thereby creating a medical-health ecosystem that encompasses the complete industry chain of R&D, production, and technological application for blood pressure measurement devices.

Shenzhen Oriental Fortune Capital Co., Ltd. (hereinafter referred to as “OFC”) is a professional venture capital management firm founded by several industry professionals with extensive experience, rich practical expertise, outstanding investment performance, and significant influence in China’s venture capital sector. OFC is committed to investing in target companies with high growth potential and IPO prospects, actively providing value-added services to portfolio companies to enhance their profitability, and striving to help them maximize enterprise value through IPOs and other means, thereby delivering satisfactory capital appreciation returns to investors.

Gree Financial Investment (full name: “Zhuhai Gree Financial Investment Management Co., Ltd.”) is an industrial investment company under the Gree Group and serves as one of the key vehicles through which the Group is building a state-owned capital investment and operation platform. Based in the Guangdong-Hong Kong-Macao Greater Bay Area and closely aligned with Zhuhai’s development strategy, Gree Financial Investment leverages the Group’s state-owned background and resource advantages to establish itself as a professional, efficient, regionally leading, and highly influential state-owned capital industrial investment platform. The Gree Group implements precise and effective investment strategies, contributing to Zhuhai City’s efforts to cultivate and introduce high-growth innovative enterprises.